Please upgrade your browser.
SFJ previously entered into an agreement with Pfizer to conduct a phase III trial in Asia of Pfizer's Inlyta (axitinib) for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma following nephrectomy.
According to the news editors, the researchers concluded: "Metastasis of renal cell carcinoma to the pancreas is a rare neoplasm accounting for 0.25-3% of all pancreatic tumors."
SFJ Pharmaceuticals Group recently announced that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase III clinical trial of Pfizer's investigational pan-HER (pan-human epidermal growth factor receptor) inhibitor, dacomitinib (PF-00299804).
I've learned a lot from all my siblings. My brother Karl taught me about how to face adversity. He had kidney cancer, and I was so impressed by the way he handled it, and he's still running his commercial cleaning business.
A single-group phase 2 trial
Pfizer Inc said its oral drug Inlyta received European approval as a second-line treatment for kidney cancer patients who do not respond to an initial chemotherapy.
Worldâs largest charity dedicated exclusively to renal malignancies releases the final report of a research project conducted by Thai H. Ho, M.D. Learn how to apply for YIA grants.
Grapefruit juice boosts cancer drug. Information about kidney cancer clinical trials.
Bayer in June said trials showed the drug prolonged the lives of patients with the aggressive type of cancer without their tumours worsening.
The WTX gene is mutated in approximately 30 percent of Wilms tumors, a pediatric kidney cancer.
|Powered by NeonCRM|